US Stock MarketDetailed Quotes
JAGX Jaguar Health
- 4.2600
- +0.2300+5.71%
Close Jul 19 16:00 ET
- 4.2600
- 0.00000.00%
Post 19:59 ET
33.69MMarket Cap0.13P/E (TTM)
4.2600High3.9600Low494.10KVolume4.0300Open4.0300Pre Close2.04MTurnover6.86%Turnover RatioLossP/E (Static)7.91MShares39.600052wk High2.81P/B30.69MFloat Cap3.072052wk Low--Dividend TTM7.20MShs Float100075500.0000Historical High--Div YieldTTM7.44%Amplitude3.0600Historical Low4.1280Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Jaguar Health Stock Forum
Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning
Jaguar Health (NASDAQ:JAGX) will report results of its Phase 3 OnTarget trial for crofelemer, a cancer supportive care drug, on July 23, 2024. The company will hold an investor webcast at 8:30 AM Eastern to discuss the results and provide updates on its cancer supportive care portfolio. The webcast will feature Jagu...
📊⚡️📊
Issuance of New European & Australian Patents Bolster IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS) and Congenital Diarrheal Disorders (CDDs)
Jaguar Health has announced the issuance of new patents in Europe and Australia to bolster IP protection for its drug crofelemer, aimed at treating Short Bowel Syndrome (SBS) and Congenital Diarrheal Disorders (CDDs). The European patent covers treatment methods for SBS and associated conditions...
No comment yet